Negotiation failed! The drug Pfizer P, which was r

Original title: negotiation failed! The drug Pfizer P, which was robbed by others, killed win thoroughly hard

Will Pfizer's COVID-19 oral medicine be reduced by 70%? On January 6, the National Health Insurance Bureau entered the stage of soul bargaining. Every year, the negotiations are very exciting. After all, lowering the price of drugs into medical insurance will save us a lot of money in the future. This time, Pfizer's COVID-19 oral medicine is the biggest attraction of the bargaining. The expected price is about 700 yuan. From the earliest online price of 2980 yuan to 700 yuan, a drop of 77%. However, the medical insurance bureau and Pfizer had a difficult negotiation for 4 hours, but finally they failed to reach an agreement because of the price differences. Pfizer did not succeed in the negotiation. Instead, domestic Azovudine and Qingfei Paidu Granules entered the medical insurance directory. In other words, Pfizer can still sell at a high price.

Selling medicine is really profitable!

A box of Pfizer COVID-19 Paxlovid, which costs 2980 yuan, can be increased to 7000 yuan for the first time, and 12000 yuan for the second time. After two hands, the price has increased more than three times. Of course, if the purchase price is lower, it will earn more.

1.2 In case there are not many boxes, there are even more ruthless ones. Some people sell medicine in the circle of friends, claiming to be "pure help without making a fortune in a country's difficulties". A box of 48000 yuan, more than 10 times the premium, is also "cheap, no counter-offer". If you learn to make a fortune in a country's difficulties, you should not sell 100000 yuan.

At this price, some people also pay the bill. After all, when it comes to drug hoarding, everyone is not soft handed. Before the liberalization, even Huaqingwen sold out of stock, and the price also increased. After the liberalization, even Huaqingwen failed. On the top of ibuprofen, manufacturers and scalpers are making soft handed money. Now, Pfizer oral medicine starts to grab hands. One box sells one box, and even generic drugs are nearly ten thousand.

All kinds of drug buying strategies on the Little Red Book and all kinds of online prescription platforms are the target of the strategy. Even the sister of milk tea is doing strategies in the circle of friends to help grab drugs, so that their own JD healthy drugs are out of stock, and the ability to bring goods is strong.

Of course, Pfizer will ultimately benefit. After all, they are the source manufacturers. If there is demand, they will not worry about selling their medicines.

In addition to Pfizer oral medicine, Pfizer's vaccine is also a hot topic.

Among the COVID-19 vaccines of the mRNA route, Pfizer can be said to be the largest. After all, Pfizer's vaccine coverage is the widest worldwide.

Although the agent of Pfizer's vaccine in China is Fosun Pharmaceuticals, the open vaccination area is limited to Hong Kong and Macao. However, with the gradual liberalization of epidemic prevention and control policies, Hong Kong customs clearance is imminent, and many mainland people are ready to go to Hong Kong and Macao to vaccinate Pfizer vaccine.

Various strategies have also been widely used. Fosun Pharmaceuticals even has the registration of vaccination in Hong Kong. Of course, it needs to pay its own money, and the price is not cheap, which is 1500 Hong Kong dollars+. At present, when the mainland goes to Hong Kong and Macao for vaccination, only vaccines targeting the original strain can be vaccinated. The bivalent vaccine targeting Omikjon is not yet open.

Oral medicine+vaccine, Pfizer makes a lot of money.

How much did you earn?

In 2021, Pfizer's revenue and profit doubled. In that year, it mainly relied on vaccine comirnaty to achieve a revenue of 36.781 billion dollars. It should be known that the revenue of Apisaban, Pfizer's best-selling drug, was only 5.97 billion dollars. A vaccine accounted for 45% of the total revenue, which could be said to be the best of the best.

In the first three quarters of 2022, the proportion of Comirnaty will decrease to 35%, and Paxlovid will fill the gap. The revenue of $17.009 billion will account for 22% of the total revenue, and the two products will account for 57% of the total revenue.

Real money printing machine.

According to Pfizer's prediction, the total revenue of vaccines will reach 34 billion dollars in 2022, while that of oral drugs will reach 22 billion dollars. If Pfizer's revenue is close to 100 billion dollars in 2022 according to the revenue ratio.

In the past, Pfizer's COVID-19 related products were mainly sold to Europe, the United States and Japan. Now, with the Chinese market, it should be no problem to break the 100 billion revenue.

For the "No. 1 Pharmaceutical Factory in the Universe", Comirnaty and Paxlovid will be epoch-making drugs in Pfizer's history.

Pfizer was founded in 1849. Charles Pfizer, a German American chemist, and Charles Earhart, a candy merchant, a pair of cousins, borrowed 2500 dollars from their father and started Pfizer in a red brick house in Brooklyn, New York. They became famous by using candy to transform insect repellents. Later, they made a lot of war money during the Civil War.

Pfizer started out on a chemical route.

In 1917, citric acid became Pfizer's flagship product, and Pfizer became one of the largest suppliers of Coca Cola; In 1944, penicillin was mass produced, and Pfizer's production accounted for more than half of the world's total; In 1949, Pfizer extracted "oxytetracycline" from the soil in the Midwest of the United States, becoming the first self-developed antibiotic under Pfizer.

In 1950, Pfizer's oxytetracycline went on the market and achieved a sales record of 60 million dollars, so Pfizer began to embark on the pharmaceutical road.

Of course, making money is also good. Feldene, an anti-inflammatory drug, was Pfizer's first product with a sales volume of $1 billion. Later, Norovo broke this record, with a global sales volume of more than $3 billion in 1999.

Of course, Pfizer's most famous product is still "small blue chip".

In 1991, Pfizer made a drug to treat cardiovascular diseases. The main component was sildenafil citrate. The effect was not obvious. Pfizer did not want to do it, but the people who received the experiment were unwilling to return the drug.

Why?

It was originally intended to expand the cardiovascular system, but the cardiovascular system did not expand successfully, but opened another part of the blood vessel. Many people who had previously "failed" did it again after taking medicine. The research shifted from the upper body to the lower body. Many experts' research on nitric oxide provided a theoretical basis for the treatment of erectile dysfunction with sildenafil.

In 1998, experts studying nitric oxide won the Nobel Prize. In March of the same year, a new drug named Viagra (Viagra, commonly known as Viagra) was born, and then became the prescription drug with the fastest sales growth at that time.

In April 1998, more than 200000 doctors wrote more than 7 million prescriptions for 3 million people, and sold more than 50 million tablets. In 1998, with the help of Viagra, Pfizer rose to prominence, with a revenue of $23.2 billion.

Then in that year, it was sung into the song.

In 1999, the sales volume of Viagra exceeded 1 billion dollars. Since then, the average annual sales volume of this small blue pill has risen steadily. In 2012, the sales volume reached a peak of 2 billion dollars (about 13 billion yuan), bringing huge returns to Pfizer.

In 2000, Viagra was approved for listing in China. The price of Viagra is more than 100 yuan, which is also hard to find. There is a black market for all of these things. The black market price can be more than 500 yuan. Of course, we still rush to buy it when we need it.

At that time, there was a patent war for Viagra, Pfizer and Chinese pharmaceutical companies.

In September 2001, Pfizer's sildenafil was granted an invention patent by the State Intellectual Property Office of the People's Republic of China, with the patent protection period ending in 2014.

However, some Chinese pharmaceutical factories can't sit still. They have already spent a lot of money to develop sildenafil. Patent protection has made their previous research useless, so they request to revoke the patent. The reason is that the molecular structure of sildenafil has been announced in Singapore before, and Pfizer has no right to apply for a patent.

After a long patent review, the Property Office revoked Pfizer's patent in 2004.

Pfizer was in a hurry. Without patents, it could not monopolize production. If it wanted to fight a price war with Chinese pharmaceutical companies, it would lose. So Pfizer sued the State Property Office and 12 pharmaceutical companies, demanding that Pfizer's patents be valid.

In fact, there have been many patent disputes in Europe and South America.

In order to obtain patents in China, Pfizer, on the one hand, lobbied American officials to put pressure on China, and the United States commented on China's patent policy; On the other hand, of course, the American Chamber of Commerce in China also makes soft threats, such as reducing investment or even withdrawing investment.

Finally, in 2006, Pfizer won the lawsuit, and the patent period was extended to 2014. However, in 2013, Lilly's Xielita Dalafei sales exceeded Viagra's, and Viagra's brilliance faded. In 2014, when the patent expired, domestic Viagra gradually encroached on Pfizer's market share.

From the perspective of Pfizer, the EU knows that it is an old trick to suppress competitors' drugs of the same kind in order to make profits. These means increased the EU's expenditure by 3 billion euros in 2000-2007.

。

Of course, the black history of Cosmos First Pharmaceutical is not limited to this:

• In 2007, Pfizer was claimed 2.75 billion dollars by the government of Kano State, Nigeria, for many deaths caused by drug testing with 200 Nigerian children in 1996
• In 2009, Pfizer was fined US $2.3 billion for exaggerating its marketing
• From 2015 to 2016, Pfizer's best-selling antidepressant drugs caused neonatal malformations, which triggered hundreds of complaints
• In 2019, a Pfizer antihypertensive drug stimulated the growth of malignant tumors

This time, the oral drugs and vaccines that Pfizer has made a lot of money are controversial.

Whether it is oral medicine or vaccine, it is still "emergency use" and has not been officially approved. Why? Because many security experiments have not been completed yet.

The mRNA vaccine is indeed a relatively advanced technology at present, but compared with the inactivated vaccine, the technology is still not mature. Since it was approved for emergency use, there has been constant controversy.

In December 2020, the FDA of the United States approved the emergency use authorization, but at the same time, there was news that the White House had put pressure on the director of the FDA. Although the director denied the rumor, the dispute did not stop.

Later, the side effect report of "9-page PDF" was reported, "420000 samples, 159000 adverse reactions and 1223 deaths". This data has been widely spread, and has not been confirmed yet.

When Paxlovid appeared in 2021, it was named as a "special drug" to reduce the severity by 90%. It was called a "drug to change the rules of the game" by Nature. Of course, after the "apotheosis", it was inevitable to seize drugs in stages, but it was useful, but not so useful.

It can only solve the virus replication at the initial stage of infection, and has no effect on the immune factor storm caused by the replicated virus; It is basically ineffective for severe patients, and only effective for the first 5 days of mild and moderate symptoms; It is meaningless for non high-risk people to hoard drugs; Self medication by high-risk people is risky because it will interact with other drugs.

Of the 27 pages of the instructions, 19 pages are devoted to drug interactions, toxicity, contraindications, etc. These are just a part of them, and there are more side effects on the way of research.

When the Chinese were scrambling for drugs, the researchers were studying the "Paxlovid rebound", that is, the phenomenon that symptoms and detectable viruses of some patients who had taken drugs disappeared at first, but reappeared a few days later, similar to what we often call "rejuvenation", which happened to President Biden of the United States and infectious disease expert Fauci.

Based on the price, side effects, drug conflicts and rebound, European and American clinics are very cautious when prescribing. According to the British health report, the prescription rate in Britain is only 0.5%, while that in the United States is 13%. However, compared with the originally expected course of treatment, it is still a big difference.

Pfizer's CEO once boasted in the middle of the year. Paxlovid's annual income was $63.48 billion. Three months later, it changed its position to $22 billion in the third quarter, cutting nearly two-thirds.

The drug hoarders should be slow.

Source: Big Cat Finance